



# Actinium Pharmaceuticals Appoints Jeannine Larrieux, Ph.D. as Director of Analytical Development to Support BLA and IND Enabling Analytical Studies for Current and Future Clinical Programs

- Dr. Larrieux brings significant experience managing analytical development quality control of immunotherapies to treat cancer and small molecule therapies at pharmaceutical and biotechnology organizations

NEW YORK, Dec. 19, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that Jeannine Larrieux, Ph.D. has been appointed Director of Analytical Development. Dr. Larrieux will be responsible for analytical assay development, conducting biologics license application (BLA) and investigational new drug (IND) enabling studies, authoring CMC analytical sections for BLA and IND filings and supporting both internal and external quality assurance (QA) and quality control (QC) efforts.

"Dr. Larrieux is an accomplished analytical professional who is bringing over 20 years of highly relevant industry experience in matters related to regulatory submissions, project management and QA/QC to Actinium," said Sandesh Seth, Actinium's Executive Chairman. "Dr. Larrieux is yet another invaluable addition to the Actinium team that will contribute enormously to the development of our clinical programs Iomab-B and Actimab-A as well as future clinical programs we hope to unveil in the near future."

Dr. Larrieux joins Actinium following analytical consulting assignments in the U.S. and Europe. Prior to this, she was Head of AS&T at Novartis where she focused on cell therapy products aimed to treat acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). Prior to Novartis, Dr. Larrieux was Laboratory Manager at Dendreon Corporation where she supported Phase 3 and Phase 4 clinical studies. In addition, Dr. Larrieux has worked at Pfizer, Purdue Pharma and Wyeth in analytical roles.

Dr. Larrieux earned her Ph.D. in Material Chemistry from Polytechnic Institute of NYU, an M.S. degree in Chemistry from Polytechnic University and a BS.c. degree in Chemistry from State University of HAITI (PAP). In addition, she is a member of the Regulatory Affairs Professionals Society (RAPS) and a member of the American Society for Quality (ASQ).

**About Actinium Pharmaceuticals, Inc.**

Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options. Actinium's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. The Company's lead product candidate Iomab-B is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. A bone marrow transplant is often the only potential cure for patients with blood-borne cancers but the current standard preparation for a transplant requires chemotherapy and/or total body irradiation that result in significant toxicities. Actinium believes Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased transplant success and survival rates. The Company is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The Company's second product candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies. Actinium is also utilizing its alpha-particle immunotherapy (APIT) technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceuticals is based in New York, NY. To learn more about Actinium Pharmaceuticals, please visit [www.actiniumpharma.com](http://www.actiniumpharma.com) and to follow @ActiniumPharma on Twitter please visit, [www.twitter.com/actiniumpharma](http://www.twitter.com/actiniumpharma).

### **Forward-Looking Statements for Actinium Pharmaceuticals, Inc.**

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Actinium Pharmaceuticals, Inc.  
Steve O'Loughlin  
Vice President, Finance and Corporate Development  
[soloughlin@actiniumpharma.com](mailto:soloughlin@actiniumpharma.com)



Source: Actinium Pharmaceuticals